Abstract | Cardiac myocyte function is dependent on the synchronized movements of Ca 2+ into and out of the cell, as well as between the cytosol and sarcoplasmic reticulum. These movements determine cardiac rhythm and regulate excitation-contraction coupling. Ca 2+ cycling is mediated by a number of critical Ca
Introduction
The incidence of congestive heart failure is increasing worldwide, despite important advances in pharmaco logical and device therapies.
1-3 Therefore, novel treatment strategies are urgently needed. An improved under standing of the molecular mechanisms involved in the pathogenesis of heart failure has led to the identifi cation of new therapeutic targets, such as the Ca 2+ handling proteins in the sarcoplasmic reticulum. Ca 2+ has critical functions as a second messenger in a number of signaling pathways in all cell types. 4 ,5 Unlike other second messengers, Ca 2+ is stored intracellularly. The membranes of the endoplasmic reticulum (and the sarcoplasmic reticulum in muscle cells), act as a major reser voir for intracellular Ca 2+ . Cytosolic Ca 2+ is main tained at basal levels by the actions of Ca 2+ channels, ATPase pumps, exchangers, transporters, and Ca 2+ binding proteins. In the heart, Ca 2+ regulates electri cal signals that determine cardiac rhythm and excitationcontraction coupling, which converts the electrical stimulus to muscle contraction. Ca 2+ might also regu late cardiac remodeling and apoptotic and necrotic cell death by activating enzymes and transcriptional gene regulatio n (Box 1).
Rapid changes in levels of intracellular Ca 2+ are crucial for heart muscle contraction (systole) and relaxation (diastole). The contractile function of individual cardiac myocytes is controlled by excitation-contraction coupl ing (Figure 1 ). The arrival of an action potential depolari zes the sarcolemma and enables a small amount of extra cellular Ca 2+ to diffuse into the cell through voltagedependent Ltype calcium channels (LTCC). This Ca 2+ influx trig gers Ca 2+ release from the sarcoplasmic reticulum through ryanodine receptor (RyR) channels. Intracellular Ca 2+ levels then rapidly increase and Ca 2+ binds to troponin C, resulting in muscular contraction. During cardiac relax ation, Ca 2+ is removed from the cytosol by two main mechanisms: extrusion through the sarcolemma and reuptake into the sarcoplasmic reticulum. Extrusion occurs through sodium/calcium exchan gers (NCXs) and reuptake is mediated mainly via activation of the cardiac isoform of sarcoplasmic/e ndoplasmic reticulu m calcium ATPase 2, SERCA2a.
Excitation-contraction coupling is modulated by other important second messengers, such as cyclic AMP (cAMP). This molecule is upregulated via activation of adenylate cyclase in response to βadrenergic stimulation coupled with stimulatory Gprotein activation. cAMP activates phosphatases and a series of protein kinases, including cAMPdependent protein kinase (PKA), 6, 7 which in turn activate βadrenergic receptor (βAR) sig naling pathways. [8] [9] [10] PKA phosphorylates several targets that have important roles in excitation-contraction coup ling. For example, phosphorylation of LTCC leads to increases in both Ca 2+ current and force genera tion;
11,12 phosphorylation of the SERCA2a inhibitor, cardiac phospholamban, reduces SERCA2a inhibition, which results in an increase in Ca 2+ resequestration into the sarcoplasmic reticulum;
13-15 and phosphorylation of troponin I reduces the sensitivity of myofilaments to Ca 2+ , leading to enhanced Ca 2+ resequestration and dia stolic relaxation.
16-18 βadrenergic stimulation, therefore, increases the rates of both contraction (positive ino tropy) and relaxation (positive lusitropy) in cardiac myocytes. 19 The PKAinduced increase in Ca 2+ current and amelio ration of SERCA2a inhibition are major factors that enhance cardiac contractility. 20 Defects in every stage of excitation-contraction coupl ing lead to diastolic and systolic abnormalities, as well as an increased propensity for ventricular arrhythmias, all of which have all been reported in patients with heart failure. These defects are the result of altered expres sion or function of proteins that are required for the mainten ance of Ca 2+ homeostasis. In this Review, we explain the association between abnormalities in Ca 2+ handling in the sarcoplasmic reticulum and heart failure, and discuss the therapeutic potential of targeting key proteins involved in this process. βARs and adenylate cyclase are possible targets for the treatment of heart failure that have been reviewed elsewhere; 21, 22 as such, they are mentione d only briefly in this Review.
Impaired Ca 2+ cycling in heart failure
The primary cause of heart failure is diastolic dysfunction resulting from impairments in myocardial relaxa tion, ventricular filling, or both. Diastolic dysfunction is also associated with systolic dysfunction. At the cellular level, the causes of impaired cardiac myocyte relaxation inc lude cytosolic Ca 2+ overload, myofilament structural changes or dysfunction, and neurohormonal activation.
In many patients with heart failure, excitationcontraction coupling is defective. A number of abnor malities of receptors, pumps, and regulatory proteins that are involved in Ca 2+ cycling have been shown in these patients. These abnormalities lead to a prolongation of the cytosolic Ca 2+ transient time and, in patients with endstage heart failure, an increase in enddiastolic Ca 2+ concentration. 23 Such changes, which are often a result of a decrease in the density or function of SERCA2a in the sarco plasmic reticu lum, impair systolic and diastolic function. An increased level of intracellular Na + in heart failure myocytes can contribute to increased cytosolic Ca 2+ loading via NCX. However, upregulation of NCX function, which might also occur in heart failure, could partially compensate for SERCA2a downregulation with respect to diastolic functio n, but would not affect systolic function.
In chronic heart failure, sustained activation of the βAR and downstream signaling pathways have adverse effects on cardiac cells. At the molecular level, βAR dysfunction is characterized by a reduction of β 1 AR density, resulting in an increased β 2 AR: β 1 AR ratio and uncoupling of βARs from Gprotein complexes. 24, 25 This desensitization is mediated by elevated Gprotein receptor kinase activity. 6 -regulated enzymes, and might also regulate the cardiac cell population by inducing hypertrophy, necrosis, or apoptosis Heart rhythm ■ Ca 2+ regulates electrical signals that determine the cardiac rhythm via ion currents and exchangers ■ β-adrenergic stimulation results in increased Ca 2+ entry into the cell, which ultimately leads to increased rates of myofilament contraction and relaxation ■ An increase in external Ca 2+ concentration induces shorting of phase 2 of the cardiac action potential, and consequently reduces the action potential duration ■ After a delay, K + channels reopen, allowing diffusion of K + out of the cell, which causes repolarization to the resting state and reduces the duration of the action potential ■ Excitation-contraction coupling converts the electrical stimulus provided by the arrival of an action potential to a mechanical response, muscular contraction ■ Ca 2+ release from the sarcoplasmic reticulum into the cytosol is required for muscle contraction: cytosolic Ca 2+ levels activate the myofilaments and modulate their contractile properties Mitochondrial function ■ Cytosolic Ca 2+ levels influence energy production and respiration, as ATP produced by the mitochondria is required for both muscle contraction and relaxation 38 and prevented cardiomyopathy in murine models. 39 Most animal models of heart failure have shown either no change or a slight decrease in the wholecell density of LTCC current in the myocardium.
40
A murine study showed that a decrease in LTCC current caused a compensatory increase in Ca 2+ leakage from the sarcoplasmic reticulum via ryanodine receptor 2 (RyR2), resulting in pathological cardiac hypertrophy and heart failure through calcineurin-NFAT signaling.
41
A reduction in expression of LTCC and Ca 2+ current has not been definitively established in human heart failure. However, the singlechannel activity of LTCC was significantly increased in human failing ventricu lar myocytes compared with nonfailing control myo cytes. 42 The basal level of LTCC phosphorylation was also increased in failing myocardium, suggesting that LTCC phosphorylation might contribute to the blunted inotropic effects of adrenergic stimulation in the failing human heart. 42, 43 Clinical trials have shown either no effect, or a detrimental effect, of LTCCblocking agents on the survival of patients with heart failure. 44 Whether LTCCinhibitors could be used to treat heart failure is, therefore, unclear. Dissociation of Ca 2+ from the EFhand domains leads to rapid oligomerization of STIM1, 52, 54 relocalization of the molecule to the junction between the plasma membrane and the endoplasmic or sarcoplasmic reticulum, and acti vation of CRAC channels in the plasma membrane. 53, 55 STIM1 directly interacts with CRAC channel protein 1, the poreforming subunit of the CRAC channels, results in the assembly of an active tetrameric complex that opens the Ca 2+ channel and allows Ca 2+ influx into the cytosol. 56 Ca 2+ influx activates calcineurin-NFAT signal ing and induces transcriptional activation of immune response and prohypertrophic genes. 57, 58 SOCE has been identified in excitable cells, inclu ding skeletal muscle fibers [59] [60] [61] and smooth muscle cells. 62 In smooth and skeletal muscle cells, SOCE might be medi ated by the comparatively nonselective, canonical tran sient receptor potential (TRPC) channels. 63 ▶ REVIEWS expressed in the heart and in slowtwitch muscle. By contrast, SERCA2b is ubiquitously expressed and has a 49aminoacid tail. This Cterminal extension, which has highly hydrophobic properties, might form an additional endoplasmic or sarcoplasmic reticulum transmembrane domain, 71 which could explain why SERCA2b has a higher affinity for Ca 2+ than SERCA2a. 72 Both SERCA2a and SERCA2b bind cardiac phospholamban and they do not differ in their sensitivity to the SERCA inhibi tor thapsigargin. 73 The third variant, SERCA2c, has a 61basepair intronic sequence between exons 20 and 21 of SERCA2a, and a short tail of six amino acids. SERCA2c has been detected in human monocytes and fetal hearts 74 and is also expressed in skeletal muscle and cardiomyocytes. 75 No shift in the relative amounts of the SERCA2 iso forms has been detected in failing human hearts. 76 However, in animal models of hypertrophic 77-79 and ischemic 80,81 heart failure, a decrease in the rate of sarco plasmic reticulum Ca 2+ uptake as well as low levels of SERCA2a have been shown. Furthermore, a reduction in SERCA2a activity with a resulting decrease in sarco plasmic reticulum Ca 2+ uptake is a consistent feature of failing cardiac myocytes in humans. Data from several studies on explanted failing human hearts (obtained during transplantation procedures) suggest that sarco plasmic reticulum Ca 2+ transport function is impaired in endstage human heart failure. Decreases in the level of SERCA2a mRNA, protein, or activity correlate strongly with decreased myocardial function and impaired contractil e force-frequency relationships. 68, 82, 83 SERCA2a activity is tightly regulated by the small inhibitory peptide cardiac phospholamban. This protein binds to SERCA2a and induces a conformational change that reduces the Ca 2+ binding affinity of SERCA2a and the rate of Ca 2+ uptake by the sarco plasmic reticulum.
84,85
In most failing human hearts, cardiac phospho lamban protein expression is unalter ed, 86,87 but a decrease in the level of cardiac phospho lamban mRNA has been reported in patients with dilated or ischemic cardio myopathies.
88,89 Interestingly, the decrease in levels of SERCA2a in failing myocardium is greater than the decrease in levels of cardiac phospho lamban; 90 there fore, the ratio of cardiac phospholamban to SERCA2a increases, resulting in increased inhibition of SERCA2a. A reduction in phosphorylation of cardiac phospho lamban can also increase SERCA2a inhibition in failing myo cardium. 91 In animal models of heart failure, phos phorylation of cardiac phospholamban was reduced at either Ser16, 92 Thr17, 93,94 or both. 95 Similarly, reduced phosphory lation of cardiac phospholamban at Ser16, but no change in phosphorylation at Thr17, was shown in samples from failing human hearts.
92, 96 The reduction in phosphory lation at Ser16 correlated with a decrease in the sensitivity of SERCA2a to high Ca 2+ levels in human failing myo cardium. 92, 96 Cardiac phospholamban is dephosphory lated by protein phosphatase 1 (PP1) 97 and, as we will discuss in more detail later in this Review, increased PP1 activity has been shown in animal models of heart failure.
98 These data suggest that the level of phospholamban phosphorylation might depend on the severity of heart failure, and could be affected by βAR signaling pathways through alterations in the activation of protein kinase A (PKA). Mutations in the PLN gene, which encodes cardiac phospholamban, are associated with human heart failure. In patients with familial dilated cardiomyopathy, muta tions in the coding region of the PLN gene have been identified. 97 PLN mutations, such as an arginine to cys teine substitution in codon 9 (Arg9Cys) and an arginine deletion in codon 14 (Arg14del), might enhance cardiac phospholambanmediated inhibition of SERCA2a acti vity.
99-101 Transgenic mice that expressed the Arg9Cys mutant developed terminal heart failure that resulted in premature death. 100 In addition, two more mutations at Arg9 (Arg-Leu and Arg-His substitutions) were identi fied in a cohort of patients with heart failure. 99 A muta tion in the coding region of the PLN gene that resulted in a termination codon (Leu39stop) was identified in two families with hereditary heart failure.
102 Patients who were homozygous for this mutation, which pre vented phospholamban expression, developed dilated cardiomyopath y and heart failure.
102
NCX has a major role in the extrusion of Ca 2+ through the sarcolemma into the extracellular space and contri butes to Ca 2+ removal during mam malian cardiac myo cyte relaxation.
103 Some studies have shown increased NCX expression in failing human hearts. 104, 105 In human heart failure, NCX upregulation might compen sate, at least in part, for any decline in SERCA2a activity because an increase in NCX acti vity might accelerate the removal of Ca 2+ from failing cardiac myocytes during relaxation. However, another study showed no change in NCX expression in myo cardium from termi nally failing human hearts.
106 A study in which the level of NCX mRNA in myocardium from failing human hearts was analyzed showed no correlation between NCX mRNA expression and the severity of disease.
107
NCX mRNA was upregulated only in endstage heart failure. 107 storage reduces excitation-contraction coupling and contributes to dysfunction of systolic contractility. 112 The most abundant acidic sarcoplasmic reticulum protein is calsequestrin (CASQ). In humans, two isoforms of CASQ have been identified; CASQ1 is found in skele tal muscle, and CASQ2 in cardiac muscle.
113 CASQ2 is primarily responsible for the Ca 2+ storage capacity of the myocardial sarcoplasmic reticulum. The protein has a high capacity and a moderate affi nity for Ca 2+ and acts as a Ca 2+ buffer that decreases the concentration of free luminal Ca 2+ to facilitate further SERCA2amediated Ca 2+ uptake into the sarcoplasmic reticulum. 113 The large Ca 2+ buffering range of CASQ2 facilitates the large storage capacity of the sarcoplasmic reticulum as well as the rapid release of Ca 2+ into the cytosol. 113 In addition, CASQ2 has a role in regula ting the open probability of RyR2 channels and, therefore, the amount of Ca 2+ release from the sarcoplasmic reticu lum. 114, 115 The levels of CASQ2 mRNA and protein do not change substantially in failing human hearts. However, CASQ2 is associated with certain types of arrhythmia, such as catecholaminergic polymorphic ventricular tachycardia (CPVT), which is characterized by stressinduced or exerciseinduced ventri cular tachycardias that lead to sudden cardiac death at young ages (9 ± 4 years). 116 In mice, CASQ2 knockout caused an autosomalrecessive form of CPVT, although Ca 2+ transients in cardiac myocytes were unaltered. 117 Mutations in CASQ2, the gene that encodes CASQ2, also cause CPVT. 118 In humans, a missense mutation in a highly conserved region of CASQ2 that resulted in an amino acid change from aspartic acid to histidine at codon 307 (Asp307His) caused autosomalrecessive CPVT. 118 The Asp307His mutation also caused RyR2 dysfunction and a CVPT phenotype in a mouse model. 119 Cardiac CASQ2 is glycosylated and then trimmed by a series of mannosidases located within distinct intra cellular compartments. 120 This glycosylation prevents premature polymerization of CASQ2, and ensures transport of the protein to the sarcoplasmic reticulum. Interestingly, defective glycosylation of CASQ2 was identified in canine ventricles following rapidpacing induced heart failure. 120 The levels of glycan forms of CASQ2 that were characteristic of a junctional sarco plasmic reticulum location were reduced by 80%, and the level of the mannose 8,9 CASQ2 glycoform, charac teristic of a rough endoplasmic reticulum location, was increased twofold in failing canine hearts compared with healthy controls. 120 Data from CASQ2 traffick ing studies in adult rats also suggested that abnormal glyco sylation might result in retention of CASQ2 in the rough endoplasmic reticulum of cardiac myocytes. 121, 122 These findings suggest that defective posttranslational processing of CASQ2 might lead to impaired CASQ2 cellular compartmentalization during heart failure.
Triadin and junctin are transmembrane sarcoplasmic reticulum proteins that form a complex with CASQ2 and RyR2. This complex, which anchors CASQ2 to the luminal membrane in close proximity to the Ca 2+ release channel, might have an important role in the regulation of Ca 2+ release from the sarcoplasmic reticulum. Triadin and junctin might be involved in luminal Ca 2+ sensing by mediating the interaction between CASQ2 and RyR2, 123 and might be required for the normal operation of Ca 2+ release. The levels of triadin and junctin are reduced in failing human myocardium. 124 However, whether this reduction causes heart failure, or if the downregulation is an adaptive response that improves Ca 2+ handling in failing cardiac myocytes, is not clear. Overexpression of triadin in adult rat ventricular myocytes increased RyR2 channel activity and arrhythmia. 125 Downregulation of junctin in failing human hearts might reduce sarco plasmic Ca 2+ leak in response to chronic βadrenergic stimulation and improve cardiac function. 126 Cardiac specific overexpression of β 1 AR in transgenic mice resulted in a decrease in junctin protein levels and pro gression of hypertrophy. 126, 127 Abnormalities in sarco plasmic reticulum protein trafficking and assembly of the Ca 2+ release complex, which result in impaired Ca 2+ release from the sarcoplasmic reticulum, might c ontribute to heart failure.
Sarcoplasmic reticulum histidinerich calciumbinding protein (HRC) interacts with triadin and SERCA2a, and might have a role in both Ca 2+ release and uptake. 127 In adult rat cardiac myocytes, overexpression of HRC increased the Ca 2+ storage capacity of the sarcoplasmic reticulum but decreased sarcoplasmic reticulum Ca 2+ release and the Ca 2+ transient duration, resulting in a reduction in contractility. 128 HRC expression is signifi cantly reduced in failing human and animal hearts. 128 This reduction might be a compensatory mechanism that increases Ca 2+ release from the sarcoplasmic reticulum in an attempt to improve cardiac function during heart failure. 128 A HRC gene polymorphism, which results in the amino acid change Ser96Ala, was associated with ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. 129 S100 calcium binding protein A1 (S100A1), a member of the S100 family of proteins that contain EFhand Ca 2+ binding motifs, is located in the sarcoplasmic reticulum, sarcomere, and mitochondria, and is highly expressed in cardiac myocytes.
130 S100A1 stabilizes RyR2 in dia stole and augments Ca 2+ release during systole. S100A1 also increases SERCA2a activity during the relaxation phase. 131 Myocardial levels of S100A1 are decreased in patients with heart failure as a result of cardio myopathy. 132 Gainoffunction and lossoffunction experiments have been used to characterize the in vivo and ex vivo positive inotropic effects of S100A1. [133] [134] [135] Cardiacrestricted overexpression of S100A1 in trans genic mice had chronic cardiac inotropic effects that were independent of βadrenergic signaling, 133 and an increase in S100A1 protein levels in isolated adult and neonatal murine cardiac myocytes enhanced their systo lic and diastolic performance through modulation of cellu lar Ca 2+ handling. 133, 134 By contrast, S100A1 deficient mice showed severely impaired inotropic and lusitropic responses to βadrenergic stimulation and acute or chronic hemodynamic stress. 135 These impair ments were at least partly caused by a reduction in cardiac Ca 2+ sensitivity. 135 A decrease in S100A1 protein levels might, therefore, contribute to Ca 2+ dysregulation and impaired contractile function in human heart failure. Interestingly, myocardial contractility is also regula ted by energy metabolism and S100A1 interacts with mito chondrial ATP synthase, resulting in an increase in the activity of the enzyme and increased production of ATP. 136 These data suggest that S100A1 might also have a role in cardiac metabolism. However, further investi gation of the potential mechanism of S100A1mediated metabolism in cardiac myocytes is required.
Sarcoplasmic reticulum Ca
2+ leakage Ca 2+ channels within the sarcoplasmic reticulum are nonselective and have highconductance cation transport properties, which facilitate rapid, localized Ca 2+ release. Abnormalities in the structure and function of the sarco plasmic reticulum Ca 2+ channels have been associated with cardiac arrhythmia and human heart failure. 137, 138 Release of Ca 2+ from the sarcoplasmic reticulum into the cytosol, which is required for contractile activation of the heart, is mediated by RyR2. 139 The RyR2 tetramer is a massive macromolecular signaling complex that binds kinases and phosphatases as well as adaptor and targeting proteins. 140 Most of these regulatory proteins, including calmodulin, CaMKII, FKBP 12.6, PKA, PP1, and calci neurin, bind to the cytosolic region of RyR2, whereas triadin and junctin bind to the luminal sarcoplasmic region. 123, [141] [142] [143] [144] [145] [146] [147] Several studies have shown increased sarco plasmic reticulum Ca 2+ leak during diastole as a result of RyR2 dysfunction in heart failure. 148, 149 This diastolic Ca 2+ leak depletes Ca 2+ stores and presumably impairs the contractility of cardiac myocytes.
Expression of RyR2 is unchanged in failing human hearts. 150, 151 However, several studies showed an increased level of PKAmediated phosphorylation of RyR2 in human heart failure. 152, 153 Chronic hyper activity of βAR signaling might lead to hyperactivation of PKA and sub sequent hyperphosphorylation of RyR2 in failing hearts. However, the effect of RyR2 hyper phosphorylation on channel activation is not clear. Some studies showed that PKAmediated phosphorylation of RyR2 activated the channel, 152, 153 whereas other studies showed that the open channel probability of RyR2 was slightly decreased in response to phosphorylation. 154, 155 Alternatively, PKAmediated phosphorylation might destabilize RyR2 channels by inducing dissociation of the acces sory protein FKBP12.6. 153 PKA levels are unchanged in patients with heart failure, but levels of phosphatases in the RyR2 protein complex, such as PP1 and protein phosphatase 2A (PP2A), are reduced. These changes resulted in a reduced rate of dephosphorylation of RyR2 (at Ser2,809 in rabbit and Ser2,808 in humans and mice) and dissociation of FKBP12.6 from the RyR2 complex. 153 Several missense mutations in cardiac RyR2 have been identified in patients with CPVT. 159 A pathogenic role of the RyR2 mutation Arg4497Cys was shown in a conditional knockin mouse model. 160 The arrhyth mia morpho logy, arrhythmia severity, and incomplete responses to βblockers, of Arg4497Cys mutant mice were similar to that of patients with CPVT.
Altered Ca 2+ -activated signaling
Abnormal Ca 2+ cycling can affect multiple signaling pathways in the heart and result in hypertrophic growth and cardiac remodeling, which frequently progress to heart failure. Changes in the morphological and func tional properties of the myocardium ultimately require reprogramming of cardiac myocyte gene expression. 161 Calcineurin (also known as Ca 2+ /calmodulin depen dent protein phosphatase 2B) is a serine/threonine phos phatase that has a key role in coupling Ca 2+ signaling to cellular responses, through interaction with NFAT. 162 
Increases in intracellular Ca
2+ levels activate calci neurin phosphatase activity. The activated protein binds and dephosphorylates NFAT, which translocates from the cytosol to the nucleus and induces gene expression. 163, 164 In the heart, NFAT interacts directly with the cardiac restricted zinc finger transcription factor GATA4, which regulates expression of hypertrophic genes, including βmyosin heavy chain, atrial natriuretic factor, and Btype natriuretic peptide. 165, 166 In mice, constitu tive activation of calcineurin resulted in progressive decom pensation, dilatation, and the development of heart failure. 167, 168 This progression recapitulated the develop ment of hypertrophic cardiomyopathy in human heart failure. 167, 168 However, the effect of pharmacological inhibition of calcineurin (using cyclosporine A) on hypertrophy in rat and mouse models is unclear. Two studies showed that treatment with cyclosporine A prevented or attenuated cardiac hypertrophy in aortic banded mice, 169, 170 but there was no evidence that the drug inhibited cardiac hypertrophy in other studies that used the same experimental model. 171, 172 High dose cyclosporine A treatment might result in severe adverse effects that could mask the therapeutic effects of the drug. 168 A complete understanding of the role of the calcineurin-NFAT pathway in the progression of hypertrophy is required to facilitate the development of antihypertrophi c drugs.
CaMKII can also be activated in response to increased levels of intracellular Ca 2+ . 173 The protein has a role in multiple cellular processes that are important in the transition from early structural heart disease to heart failure and sudden death, 173 including regulation of hypertrophic growth (mediated by class II histone deacetylase), MEF2 transcriptional activity, and inflam matory responses via activation of NFκB. 173 Consistent with the role of CaMKII in the regulation of hyper trophic gene expression, CaMKII expression and acti vity correlated with the progression of heart failure in patients with structural heart disease postmyocardial infarction. 174, 175 Overexpression of CaMKIIδ in the hearts of transgenic mice induced a hypertrophic phenotype that rapidly transitioned to dilated cardiomyopathy and abnormal intracellular Ca 2+ homeostasis, 176 resembling the remodeled myocardium in human heart failure. By contrast, CaMKII inhibition in animal models, by either genetic or pharmacological approaches, pre vented phenotypic changes that are associated with heart failure, such as arrhythmias, hypertrophy, and myocardial dysfunction. [177] [178] [179] Importantly, CaMKII might have a role in the regu lation of myocyte Ca 2+ homeostasis. 180 The protein can phosphorylate and, therefore, modulate the function of key Ca 2+ handling proteins, such as cardiac phospho lamban, RyR2, and LTCC. 173 CaMKIIdependent phosphory lation of cardiac phospholamban at Thr17 can lead to an increase SERCA2a activity and thereby accel erate sarcoplasmic reticulum Ca 2+ transport. 181 Cardiac phospholamban is phosphorylated at Ser16 by PKA and at Thr17 by CaMKII, but the relative importance of these dual phosphorylation sites in the regulation of cardiac contractility is difficult to assess. A number of studies showed that phosphorylation at Ser16 was required to allow phosphorylation at Thr17 and so maximize the contractile effects of βadrenergic stimulation. [182] [183] [184] However, Thr17 phosphorylation that was independent of Ser16 phosphorylation has also been reported. 185, 186 In mice, targeted inhibition of CaMKII activity using an inhibitory peptide resulted in a substantial decrease in phosphorylation of phospholamban at Thr17, but had no effect on phosphorylation at Ser16. 186 The mice develope d dilated heart failure. 186 CaMKII can phosphorylate RyR2 at Ser2,808 (or Ser2,809, depending on species)-which is also a PKA phosphorylation site-and at other sites, including Ser2,815. This phosphorylation increases the acti vity of the RyR2 channels. 187 Endogenouse CaMKII increased the amount of Ca 2+ release from the sarcoplasmic reticu lum for a given sarcoplasmic reticulum Ca 2+ content in intact cardiomyocytes. 188 Consistent with this finding, transgenic mice overexpressing CaMKIIδc (the major cardiac isoform) had an increased Ca 2+ spark frequen cy (indicative of diastolic spontaneous SR Ca 2+ release) and low diastolic Ca 2+ content compared with wild type mice. 189 Overexpression of CaMKIIδc causes heart failure. 189 CaMKII also associates with LTCC complexes and increases the open probability of the channels, result ing in an increase in Ca 2+ current and augmentation of cellular Ca 2+ signaling via a process called facilitation. 190 CaMKIIdependent facilitation of LTCCs requires Thr498 phosphorylation in the β2a subunit to enhance regulatory phosphorylation. 191 A role of CaMKII in the development of early afterdepolarization and arrhythmias through LTCC activation has been shown in mouse models. 190, 192 Increases in the speed of sarco plasmic reticulum Ca 2+ uptake and release as a result of CaMKIImediated phosphorylation of Ca 2+ handling proteins might provide more time for diastolic filling of the ventricles at higher heart rates.
Potential therapeutic strategies
Improvements in knowledge of Ca 2+ dynamics in health and disease have led to increased understanding of the therapeutic potential of targeting Ca 2+ handling proteins. A number of pharmacological and gene therapy strategies aimed at restoring the function of the sarcoplasmic reticu lum-either by increasing Ca 2+ uptake or preventin g Ca 2+ leakage-have been investigated (Table 1) .
Restoring Ca 2+ uptake Modulation of SERCA2a activity is critical for improv ing Ca 2+ uptake by the sarcoplasmic reticulum. SERCA2a overexpression leads to an improvement in cardiac func tion in many animal models of heart failure. Transgenic rats with increased SERCA2a expression showed enhanced contractility and better survival after pres sure overload than wildtype rats. 193 Similarly, initial data indicated that SERCA2a restoration by gene trans fer increased contractility in isolated failing human cardiac myocytes. 194 These data, which have been validated in independent animal studies, 195, 196 support the hypo thesis that in vivo gene delivery of SERCA2a could rescue the heart failure phenotype. Furthermore, SERCA2a overexpression in failing rat hearts increased the phosphocreatine:ATP ratio 197 and decreased the oxygen cost of left ventricular contraction. 198 These find ings suggest that restoration of sarcoplasmic reticulum Ca 2+ transport could normalize energy metabolism and utilization in failing hearts.
In many smallanimal studies, adenoviral delivery of SERCA2a has been used to restore SERCA2a expres sion in failing hearts. 199, 200 However, expression of adeno virally delivered transgenes is shortlived and the adenoviral vector induces an inflammatory response. 201 To avoid these problems, new vectors, such as various recombinant adenoassociated virus (AAV) serotypes, are now being used. These vectors are nonpathogenic, nonreplicative, and nonintegrating. 202 In pigs with volumeoverload heart failure, an increase in sarcoplasmic reticulum Ca 2+ uptake via AAVmediated SERCA2a gene transfer was beneficial for maintenance of cardiac function. 196 In this study, the viral vector contain ing SERCA2a was administered by intracoronary artery infusion, and ventricular remodeling and improve ments in cardiac parameters (including ejection fraction and peak left ventricular pressure rate) were observed 2 months after SERCA2a gene transfer. Improvements in left ventricular function have also been reported in sheep with rapidpacinginduced heart failure. 203 Other animal studies have shown an association between SERCA2a overexpression and reduced fre quency of arrhythmias. 195, [204] [205] [206] However, in one study involving a rat model in which SERCA2a was constitu tively overexpressed, investigators found a delay in myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. 207 Notably, though, this latter study did not involve gene transfer of SERCA2a and the overexpression of SERCA2a was not evident at the protein level. One of the early con cerns with SERCA2a overexpression was that, with addi tional SERCA2a pumps, the SR would trigger calcium release and cause arrhythmias, especially if the RyR2 are leaky. 208 However, experimental models have shown that SERCA2a overexpression decreased ventri cular arrhyth mias in both small 204 and large 195 animal models of isch emia reperfusion. Morerecent studies have shown that overexpression of SERCA2a suppresses electrical alter nans, 205 interrupting an important pathway leading to cardiac fibrillation, and decrease SR Ca 2+ leak in a model of advanced heart failure. 206 In a rat model of heart failure induced by myocardial infarction, SERCA2a gene therapy stabilized sarcoplasmic reticulum Ca 2+ load, reduced RyR2 phosphory lation, and decreased Ca 2+ leakage from the sarcoplasmic reticu lum. 206 These data suggest that SERCA2a has positive inotropic and lusitropic effects, and SERCA2a gene therapy could have antiarrhythmic effects in patients with heart failure. CUPID (Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease), the first clinical trial of AAV1 delivery of SERCA2a in patients with advanced heart failure, began in 2007. The main objective was to investigate the safety and bio logical effects of restoring SERCA2a activity in patients with advanced heart failure. Phase I was an open label, sequentialdoseescalation study in nine patients with advanced heart failure (NYHA class III or IV). DNAseresistant particles (DRP). There were no unexpec ted safety concerns and several patients showed improvements in a number of relevant para meters, including heart failure symptoms and cardiac func tion, at 6month followup. The phase I trial, therefore, demon strated safety and efficacy of the therapy despite the small number of enrolled patients.
Phase II of the CUPID trial was a doubleblind, placebo controlled, randomized study of 39 patients with advanced heart failure. 210 In this study, the partici pants received either placebo or one of three doses of AAV1-SERCA2: 6 × 10 11 DRP (lowdose), 3 × 10 12 DRP (middose) or 1 × 10 13 DRP (highdose). Each dose group contained eight patients. At 6 months of followup, the patients treated with highdose AAV1-SERCA2a showed improvement or stabilization of heart failure symptoms (assessed using the NYHA classification and Minnesota Living With Heart Failure Questionnaire), functional status (assessed using a 6 min walk test and measurement of maximal oxygen consumption), and hemodynamic performance (left ventricular ejection fraction and left ventricular endsystolic volume), as well as a decrease in Additional beneficial effects shown in a rat model of myocardial infarction when S100A1 gene therapy was combined with β-AR blockers 259 Abbreviations: AAV, adeno-associated virus; β-AR, β-adrenergic receptor; CaMKII, calcium/calmodulin-dependent protein kinase type II; IPP-1, endogenous protein phosphatase 1 regulatory subunit 1A; RyR2, ryanodine receptor 2; S100A1, S100 calcium binding protein A1; SERCA2a, sarcoplasmic and endoplasmic reticulum calcium ATPase 2a; SUMO-1, small ubiquitin-related modifier 1.
levels of the heart failure biomarker Nterminal Btype natriuretic propeptide. At 12 months followup, a signifi cant decrease in cardiovascular events (hospitalizations related to heart failure, episodes of worsening of heart failure, death, or the requirement for left ventricu lar assist devices or cardiac transplant) was evident in the patients who received highdose AAV1-SERCA2a compared with those who received placebo (HR = 0.12, P = 0.003). Moreover, during the 12month study, the estimated average duration of cardiovascular hospitali zations was considerably shorter for patients in the high dose AAV1-SERCA2a group than in the placebo group (0.4 days versus 4.5 days). The primary end point success criteria were defined as achieving efficacy in either the grouplevel analysis, with improvement in at least two of the four efficacy domains (symptomatic, functional, biomarker, and left ventricular function or remodeling), the individuallevel analysis, or Kaplan-Meier analysis of the outcome end point (time to death, or requirement for ventricular assist device or transplantation). These analyses showed that treatment with highdose AAV1-SERCA2a was better than placebo. Statistical significance for all three criteria was defined as P <0.2, rather than P <0.05, because additional requirements were imposed on the study outcomes to control for the probability of obtaining positive study results by chance alone. Two clinical trials of AAV1-SERCA2a therapy in patients with heart failure are ongoing. A randomized, doubleblind study of 16 patients who have received a left ventricular assist device for an accepted clinical indication is being carried out in the UK to evaluate the safety and feasibility of AAV1-SERCA2a therapy, and a Phase 2 trial in patients with severe heart failure is being conducted in France to evaluate structural changes in response to the therapy.
Reducing SERCA2a inhibition by targeting cardiac phospholamban is an alternative strategy for increasing SERCA2a activity. Cardiac phospholamban modulation using antisense RNA, 211 a dominantnegative phospho lamban mutant, 212 or cardiacphospholambantargeted antibodies can increase SERCA2a activity. 213 However, pharmacological approaches to cardiac phospholamban modulation have not been successful because of non specificity of the pharmacological agents. 91 An in vitro study showed that siRNAmediated inhibition was not sufficient for modulation of cardiac phospholamban in cardiac myocytes, perhaps owing to poor stability of the RNA transcript. 214 However, myocardial phospho lamban expression silencing, using an AAV9 vector encoding a short hairpin RNA, resulted in heart failure rescue, increased SERCA2a activity, and improved left ventri cular function in aorticbanded rats. 215 This result suggests that AAVmediated RNAinterference therapies might be beneficial for patients with cardiac hypertrophy and heart failure.
The serine/threonine phosphatases PP1 and PP2 have a role in regulation of cardiac contractility. 216 In particular, the negative regulator of Ca 2+ cycling PP1, which localizes to the sarcoplasmic reticulum, has been implicated in the regulation of the βAR response. 217 Dephosphorylation of phospholamban restores inhibition of SERCA, and inhi bition of Ca 2+ uptake into the sarcoplasmic reticulum 218 and an increase in PP1 acti vity 219, 220 was shown in failing human hearts. PP1 is regulated by endogenous protein phosphatase 1 regulatory subunit 1A (IPP1; also known as protein phosphatase inhibitor 1). 221 IPP1 is activated by PKAmediated phosphorylation at Thr35 and specifi cally inhibits PP1 activity. The protein could, there fore, act an amplifier of βadrenergic responses in the heart. 222, 223 In heart failure, IPP1 expression is decreased and the protein is dephosphorylated and inactive. 224 The decrease in the level of active IPP1 results in a reduc tion in PP1 inhibition, activation of cardiac phospho lamban, and inhibition of SERCA2a activity.
221 PP1 inhibitors could, therefore, potentially be used to increase SERCA2a acti vity in patients with heart failure. In rats with heart failure, this approach enhanced contracti lity under basal conditions and after βadrenergic stimu lation. 225 In another study, indu cible overexpression of IPP1c in mouse hearts increased cardiac phospho lamban phosphory lation at Ser16, but had no effect on phosphorylation of RyR2 at Ser2,808, troponin I at Ser23 or Ser24, or myosin binding protein C at Ser282. 226 These data confirm that IPP1c specifically inhibits cardiac phospholamban. In addition, IPP1c expres sion improved postischemic cardiac performance 226 and had cardioprotective effects (namely, attenu ation of the endoplasmic reticulum stress response) in adult trans genic mice. 226 IPP1c overexpression enhanced cardiac contractility in young mice, but resulted in contractile dysfunction and ventricular dilatation in response to βadrenergic stimulation in aged mice. 227 By contrast, IPP1cmediated, PP1specific inhibition increased Ca 2+ uptake into the sarcoplasmic reticulum without direct modification of sarcoplasmic reticulum Ca 2+ release in rat cardiac myocytes. 228 These data suggest that IPP1c could be an interesting new target for gene therapy in heart failure.
The posttranslational modification of small ubiquitin related modifier 1 (SUMO1) could be targeted to increase SERCA2a activity. SUMO1 is a unique poly peptide that covalently conjugates to target proteins. This binding, termed SUMOylation, regulates many aspects of protein function, such as sub cellular localization, protein-protein interactions, and transcriptional acti vity. 229 A number of target proteins that are regulated by SUMOylation have been implicated in human disease. 230 For example, a decrease in lamin A SUMOylation could be a causative factor in familial dilated cardiomyopathy; two different mutations in lamin A have been identi fied in patients with this disease. 231, 232 These mutations, which cause the aminoacid substitutions Glu203Gly and Glu203Lys, are likely to lead to defective lamin A SUMOylation as well as alterations in nuclear morpho logy and the sub cellular localization of lamin A. 232 We have shown that the activity and stability of SERCA2a in cardiac myocytes is modulated by SUMO1, and that cardiac expression of SUMO1 is significantly reduced in humans and animals with heart failure. 233 Cardiac specific overexpression of SUMO1 in transgenic mice restored SERCA2a function, improved hemo dynamic performance, and signifi cantly increased survival follow ing thoracic aortic constriction. 233 Consistent with these findings, a longterm cardiac benefit of SUMO1 over expression (using AAV9mediated SUMO1 gene deliv ery) has been shown in mouse models of heart failure. Transgenemediated SUMO1 overexpression rescued pressureoverloadinduced cardiac dysfunction concomi tantly with increased SERCA2a function and improved left ventri cular dilatation, functional deterioration, and hemodynamic performance 2 months after gene transfer (4 months after thoracic aortic constriction).
233 SUMO1 over expression also significantly reduced mortality among the mice with heart failure (P <0.05). 233 Depletion of cardiac SUMO1 using AAV9mediated delivery of a small hairpin RNA in normal mice resulted in a decline in SERCA2a function and expression, and a dramatic increase in mortality. 233 Importantly, these beneficial effects of SUMO1 overexpression did not occur when SERCA2a was downregulated, 233 suggesting a SERCA2a dependent role of SUMO1 in cardiac function. Further studies are required to define the molecular mechanism of SERCA2a regulation by SUMOylation and to investi gate the association between low SUMO1 expression and heart failure.
Preventing Ca
2+ leak Hyperphosphorylation of RyR2 by PKA or CaMKII destabilizes the channel and might cause channel dys function. 234, 235 Two strategies for enhancing RyR2 stabili zation-increasing FKBP12.6 binding and reducing hyperphosphorylation-have been investigated. Several animal studies have been carried out to investigate the effects of FKBP12.6 overexpression in failing hearts. In one study, adenovirusmediated FKBP12.6 over expression reduced Ca 2+ leakage from the sarcoplasmic reticulum as well as Ca 2+ spark frequency and amplitude in isolated rabbit cardiac myocytes. 236 In another study, cardiacspecific overexpression of FKBP12.6 in mice led to significantly improved cardiac function after myo cardial infarction. 237 Improved cardiac function was also shown in transgenic mice that overexpressed a mutant form of FKBP12.6 with a high binding affinity for hyper phosphorylated RyR2 in vitro. 237 These results support the hypothesis that increased binding of FKBP12.6 to RyR2 might improve cardiac function in heart failure. 237 Pharmacological strategies aimed at reducing Ca 2+ leakage through RyR2 have also been investigated. These strategies involve the use of agents that interact with RyR2 and inhibit Ca 2+ release from the sarco plasmic reticulum, either by altering the gating of the RyR2 channel or controlling ion translocation. Unfortunately, most of the classic RyR2targeting drugs, such as dantro lene and flecainide, have unacceptable adverse effects or lack longterm efficacy. 238, 239 JTV519 (also known as K201) is a promising new drug with cardioprotective effects. 240 The drug is a 1,4benzothiazepine derivative that has structural similarities to diltiazem, a voltage dependent LTCC blocker used in the treatment of hyper tension and some types of arrhythmias.
241 JTV519 has cardioprotective and antiarrhythmic properties. 242, 243 The agent improved the contractility of paced hearts and prevented development of heart failure in dogs, prob ably by preventing dissociation of FKBP12.6 from RyR2 and, therefore, improving defective channel gating.
244
JTV519 treatment also increased FKBP12.6 binding to hyperphosphorylated RyR2 and improved cardiac function in dogs with pacinginduced heart failure. 244 In guinea pigs 245 and rats, 246 JTV519 prevented myocardial injury caused by ischemia, and provided moreeffective myocardial protection than Ca 2+ channel blockers and β 1 AR blockers. 247 In one study, the presence of FKBP12.6 was not required for JTV519 function and the drug did not prevent delayed afterdepolarizations and ventri cular arrhythmias in a mouse model of CPVT. 248 The suggestion that FKBP12.6 might be necessary for RyR2 conformational stabilization during the closed state is still controversial. However, JTV519 has clear benefi cial effects in heart failure and most studies have shown that the drug improves arrhythmia induced by defective RyR2 protein.
Rycals (CPU0213, S107, and S44121) are drugs that stabi lize RyR2-FKBP complexes and inhibit Ca 2+ leakage from the sarcoplasmic reticulum; they could, therefore, also have beneficial effects in patients with heart failure. 249 In one study, the rycal S107 reduced bio chemical and histo logical evidence of skeletal muscle damage, impro ved skeletal muscle function, and increased exercise performance in wildtype mice subjected to intensive exercise and in a mouse model of Duchenne muscular dystrophy. 250 To our knowledge, cardioprotective effects of rycal drugs have not yet been shown. However, the efficacy of S44121 is currently being evaluated in patients with chronic heart failure who are at risk of ventricular arrhythmias. 251 Suppression of CaMKII hyperactivity after chronic βAR stimulation has been suggested as a therapy for heart failure. However, whether elevated CaMKII activity is a causa tive factor in the development of heart failure or a consequence of the disease is not clear. 252 Pharmacological inhibition of CaMKII using KN92 and KN93 reduced RyR2 phosphory lation and Ca 2+ leak from the sarco plasmic reticulum in human myocardium. 253 However, these drugs are not specific inhibitors of CaMKII, but rather inhibit all CaMK iso forms, as well as LTCC. 254 Peptide inhibitors of CaMKII have low potency as well as poor specificity (they also inhibit other CaMKs and PKA). 255 Cardiacspecific CaMKII inhibitors that could be used to treat patients with steadystate heart failure are not currently available.
Another potential target for heart failure therapy is the RyR2stabilizing protein, S100A1. Reduced S100A1 expression has been implicated in cardiomyopathies, 256 and animal models have shown the potential of S100A1 gene therapy for treatment of heart failure. [257] [258] [259] For example, in rat models of heart failure, AAV6mediated overexpression of S100A1 improved cardiac function parameters, including ejection fraction, and reversed left ventricular remodeling. 259 Adenovirusmediated S100A1 overexpression also improved the function of failing cardiac myocytes isolated from patients with ischemic heart failure. 260 This result suggests that S100A1 could be a therapeutic target in human heart failure. The safety and efficacy of coronary venous AAV9-S100A1 delivery has been shown in a pig model of postischemic heart failure; contractile function and cardiac remodeling were significantly improved. 261 However, this system has not yet been evaluated in human heart failure.
Conclusions
Improved understanding of the mechanisms of Ca 2+ cycling in cardiac cells has led to the development of novel therapeutic strategies for heart failure. These strate gies include the targeting of proteins implicated in Ca 2+ cycling abnormalities, such as Ca 2+ handling proteins in the sarcoplasmic reticulum. Targeting these proteins to enhance Ca 2+ uptake into the sarco plasmic reticulum or block sarcoplasmic reticulum Ca 2+ leakage could have substantial therapeutic benefits in patients with heart failure. Several novel therapies are currently being evaluated in animal models, and the bene ficial effects of SERCA2atargeted therapies in patients with heart failure have been shown in clini cal trials. A focus on Ca 2+ handling proteins will ulti mately guide the future development of novel treatment modalitie s for patients with heart failure. 
Review criteria
A search for original articles published between 1970 and 2012 and focusing on the sarcoplasmic reticulum was performed in MEDLINE and PubMed. The search terms used were "sarcoplasmic reticulum", "calcium", "SERCA2a", and "ryanodine receptor", alone and in combination. All articles identified were English-language, full-text papers. We also searched the reference lists of identified articles for further relevant papers. 
